Global Business Reports


Irina Negoita, James Hogan, Lubo Novak, Karl Reilly

Taiwan Pharmaceuticals & Biotechnology 2015

June 16, 2015

If government support is considered to be fundamental to an industry’s success, as could be argued in the case of the Taiwan’s information technology industry, the country’s pharmaceuticals and biotechnology industry is well positioned, as the government’s support cannot be questioned over the course of the last three decades. From 1984 to 2013, the National Development Fund, Taiwan’s government backed investment fund, has invested NT$12.4 billion into the pharmaceutical and biotechnology sector, including direct investments of NT$4.7 billion into thirteen pharmaceutical and biotechnology companies and a further NT$7.7 billion into twenty-four biotech-focused venture capital firms.

Aside from a supportive government, Taiwan offers a host of benefits that make it very attractive for future investors. Taiwan’s geographic location makes it an effective entry point for foreign companies that are interested in Asian markets, including China. PIC/S compliance, a high number of English speakers and research excellence have resulted in an extensive pipeline of potential breakthrough drugs. Taiwan’s most important strength may be its people, who provide an extensive talent pool which is being further enriched by the return of many highly skilled and successful Taiwanese from countries such as the United States.


Featuring exclusive interviews with:

Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), MOEA – Dr. Chien-Hsin Daniel Cheng, Former Director
Ministry of Health and Welfare (MOHW), Government of Taiwan – Dr. Ming-Neng Shiu, Vice-Minister
Taiwan Bio Industry Organization (TBIO) – Dr. Johnsee Lee, Honorary Chairman
Taiwan Generic Pharmaceutical Association (TGPA) – Samuel Wang, President
Taiwan Food and Drug Administration (TFDA) – Dr. Shiow-Ing Wu, Deputy Director-General
Pfizer Taiwan – Kevin Liu, Director of PAP&C and Market Access
GlaxoSmithKline (GSK) – René Jensen, Vice President and General Manager
PwC Taiwan – Lily Wong, Advisory Partner and Health Industries Leader
Lotus Pharmaceutical Co. – Renaat Janssen, CEO
Standard Chem. & Pharm. Co. – Roy Fan, CEO
Formosa Laboratories – Dr. C.Y. Cheng, President
Taigen Biotechnology – Dr. Ming-Chu Hsu, Chairman and CEO


Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.


Ramoth Services supports mines with engineering and construction in Ghana.